Identification of the angiogenic endothelial-cell growth factor-1/thymidine phosphorylase as a potential target for immunotherapy of cancer

Leiden University, Leyden, South Holland, Netherlands
Blood (Impact Factor: 10.43). 07/2006; 107(12):4954-60. DOI: 10.1182/blood-2005-09-3883
Source: PubMed

ABSTRACT Characterization of the antigens recognized by tumor-reactive T cells isolated from patients successfully treated with allogeneic HLA-matched hematopoietic stem cell transplantation (SCT) can lead to the identification of clinically relevant target molecules. We isolated tumor-reactive cytotoxic CD8(+) T-cell (CTL) clones from a patient successfully treated with donor lymphocyte infusion for relapsed multiple myeloma after allogeneic HLA-matched SCT. Using cDNA expression cloning, the target molecule of an HLA-B7-restricted CTL clone was identified. The CTL clone recognized a minor histocompatibility antigen produced by a single nucleotide polymorphism (SNP) in the angiogenic endothelial-cell growth factor-1 (ECGF1) gene also known as thymidine phosphorylase. The SNP leads to an Arg-to-His substitution in an alternatively translated peptide that is recognized by the CTL. The ECGF1 gene is predominantly expressed in hematopoietic cells, although low expression can also be detected in other tissues. The patient from whom this CTL clone was isolated had mild graft-versus-host disease despite high numbers of circulating ECGF-1-specific T cells as detected by tetramer staining. Because solid tumors expressing ECGF-1 could also be lysed by the CTL, ECGF-1 is an interesting target for immunotherapy of both hematologic and solid tumors.

Download full-text


Available from: M.G.D. Kester, Aug 25, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Peu d'antigènes tumoraux présentent à la fois une expression dans un grand nombre de cellules tumorales et exercent un rôle vital pour leur développement. Mon travail de thèse a consisté à étudier les réponses en lymphocytes T dirigées contre deux de ces protéines : la Survivine et la Midkine. Nous avons démontré que ces deux protéines induisent spécifiquement des lymphocytes T CD4+ et CD8+ capables de reconnaître des cellules tumorales. Nous avons également identifié les séquences immunogéniques (épitopes T) dans ces antigènes. Deux épitopes CD4 et CD8 de la Midkine sont localisés dans le peptide signal. Notre étude montre que la Midkine constitue une nouvelle cible pour la vaccination contre de nombreux cancers et propose des séquences peptidiques originales comme candidats vaccins.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Almost 100 years ago, Ehrlich and coworkers observed the presence of infiltrates of mononuclear cells around or inside tumor lesions [1]. This finding led them to propose that tumors could be recognized and inhibited by the ‘magic bullets’ of the immune system. At the end of the 19th century, studies were initiated that aimed at actively immunizing cancer patients against their own cancerous tissue. During the subsequent decades, cancer patients were nonspecifically immune-stimulated with relatively crude leukocyte extracts such as transfer factor, immune- RNA, bacterial extracts such as bacillus Calmette- Guerain, Coley’s toxin or levamisole. These studies were initiated in spite of the fact that little was known about the various components of the immune system that could react against cancer, and even less was known about the structures on cancer cells that can be recognized by the immune system.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Despite optimal supportive care and high-resolution HLA matching, complications such as GVHD and infection remain major barriers to the success of allogeneic HCT (allo-HCT). This has led to growing interest in the non-HLA genetic determinants of complications after allo-HCT. Most studies have examined genetic predictors of GVHD, relapse, and mortality and have focused on 3 main areas: minor histocompatibility antigen (miHAs), inflammatory mediators of GVHD, and more recently NK cell-mediated allorecognition. The genetic basis of other outcomes such as infection and drug toxicity are less well studied but are being actively investigated. High-throughput methodologies such as single nucleotide polymorphism arrays are enabling the study of hundreds of thousands of genetic markers throughout the genome and the interrogation of novel genetic variants such as copy number variations. These data offer the opportunity to better predict those at risk of complications and to identify novel targets for therapeutic intervention. This review examines the current data regarding the non-HLA genomics of allo-HCT and appraises the promises and pitfalls for integration of this new genetic information into clinical transplantation practice.
    Biology of Blood and Marrow Transplantation 03/2007; 13(2):127-44. DOI:10.1016/j.bbmt.2006.10.018 · 3.35 Impact Factor
Show more